Of all the possible side effects that come with taking a GLP-1, losing your hair is perhaps one of the scariest. The good ...

At World Sleep 2025, a discussion group examined the emerging role of GLP-1 receptor agonists in obstructive sleep apnea (OSA ...

Pfizer enters the obesity drug market with its Metsera acquisition, aiming to challenge leaders Eli Lilly and Novo Nordisk.

MyChart Central is getting a makeover. UpToDate is getting a chatbot. And clinicians are getting frustrated at President ...

Brooke Sears fought for more than two years to get a PCOS diagnosis after doctors told her she just needed to lose weight.

Recently FDA-cleared, adaptive deep brain stimulation is gaining global traction, offering real-time, personalized therapy ...

Viking Therapeutics targets obesity and MASH with high-risk prospects, trial concerns, and strong funding, but lags leaders ...

A novel strategy for people with opioid use disorder has the potential to transform lives and improve outcomes, and may ...

Placebo-subtracted mean weight loss up to 14.1%after 28 weeks with no plateauPotential for best-in-class tolerability with minimal diarrhea ...

At the 61st annual European Association for the Study of Diabetes Conference (EASD) this week in Vienna, Austria, glucose monitoring company Dexcom introduced its new offering, the Dexcom Smart Basal, ...

The company, which is developing a competitor to Cobenfy, aims to become one of rare biotechs to price a large IPO of late.